Topical Bactrim (Trimethoprim-Sulfamethoxazole) Should Be Avoided During Pregnancy
Avoid topical trimethoprim-sulfamethoxazole (Bactrim) during pregnancy due to potential risks of preterm birth, low birthweight, and kernicterus, despite limited specific data on topical formulations.
Key Evidence and Reasoning
FDA Drug Label Classification
The FDA classifies Bactrim as Pregnancy Category C and explicitly contraindicated in pregnant patients 1. The drug label states that "sulfonamides pass the placenta and are excreted in the milk and may cause kernicterus" 1. This contraindication applies to the drug compound itself, regardless of route of administration.
Guideline Recommendations for Systemic Use
The most recent and authoritative guidance comes from the 2025 North American Clinical Practice Guidelines for Hidradenitis Suppurativa, which provides a conditional recommendation to avoid oral co-trimoxazole (trimethoprim/sulfamethoxazole) in pregnant patients due to increased risk of:
- Preterm birth
- Low birthweight
- Kernicterus 2
This recommendation carries low-quality evidence but reflects expert consensus on potential fetal harm 2.
Supporting Evidence from Other Guidelines
The 2020 ERS/TSANZ respiratory guidelines recommend avoiding co-trimoxazole during the first trimester and considering it only "possibly safe" in the second and third trimesters, with specific warnings about:
- Sulfonamide-associated hyperbilirubinemia in neonates
- Fetal hemolytic anemia when used at delivery
- Need for folic acid supplementation (5 mg/day) if used in T3 3
Research Evidence on Pregnancy Risks
A 2018 nested case-control study (n=77,429 pregnancies) found TMP-SMX exposure was associated with nearly 3-fold increased risk of spontaneous abortion (AOR 2.94,95% CI 1.89-4.57) after controlling for confounders, indication bias, and protopathic bias 4.
Notably, a 2025 randomized controlled trial in Zimbabwe found no benefit of TMP-SMX prophylaxis during pregnancy on birth weight, though it did not demonstrate increased adverse events in this specific population 5.
Topical vs. Systemic Considerations
Critical Caveat About Topical Formulations
While the evidence cited primarily addresses oral/systemic TMP-SMX, the following principles apply to topical use:
- Topical antibiotics generally have minimal systemic absorption 6
- However, no specific safety data exists for topical TMP-SMX in pregnancy 6
- The FDA contraindication does not distinguish between routes of administration 1
- Given the established risks with systemic exposure and lack of safety data for topical use, the precautionary principle applies
Safer Alternatives for Topical Therapy
The 2025 HS guidelines suggest that for pregnant patients requiring topical antibiotics:
- Topical antibiotics can be used with an approach similar to other HS populations (conditional recommendation, very low quality) 2
- Chlorhexidine antiseptic washes are suggested as unlikely to be associated with increased pregnancy risks 2
- Bleach baths and zinc pyrithione are also considered safe alternatives 2
Clinical Algorithm
When considering topical antibiotics in pregnancy:
- First-line: Use topical clindamycin or erythromycin (established safety profiles in pregnancy)
- Antiseptic alternatives: Chlorhexidine washes, bleach baths, or zinc pyrithione
- Avoid: Topical TMP-SMX due to lack of safety data and systemic contraindication
- If systemic antibiotics needed: Use cephalexin, azithromycin, or clindamycin (all have moderate-quality evidence for safety) 2
Common Pitfalls
- Do not assume topical formulations are automatically safe just because systemic absorption is lower—the FDA contraindication and lack of specific safety data should guide decision-making
- Do not use TMP-SMX in the third trimester or near delivery due to kernicterus risk 3, 1
- Remember that even "possibly safe" alternatives in T2/T3 require folic acid supplementation if sulfonamides are absolutely necessary 3